# Sam Clark

> Sam Clark, MD, PhD, is the founder and CEO of Terran Biosciences, a CNS-focused platform biotech he started in 2017 from his medical school dorm room with $10,000. A neuroscientist trained at MIT and Columbia, Clark has built one of the largest psychedelic development programs in the industry, is the named inventor on more than 200 patent applications, and holds the world's first patents for new forms of psilocybin and MDMA. Terran pairs a medicinal-chemistry drug design engine with an FDA-cleared neuroimaging software platform and a pipeline of late-stage assets licensed from Sanofi and Pierre Fabre.

- **Role:** Founder and CEO at Terran Biosciences
- **Organizations:** Terran Biosciences
- **Nationality:** American
- **Education:** BS, Neuroscience, Massachusetts Institute of Technology (MIT), MD and PhD, Columbia University
- **Known for:** Named inventor on over 200 patent applications in neuropsychiatry, Sole inventor on the world's first patented new forms of psilocybin and MDMA, Built one of the largest psychedelic development programs in the industry

## Career timeline

- **2017** — Founded Terran Biosciences from his medical school dorm room with a $10,000 seed investment
- **2023** — Terran announces new breakthroughs in the chemistry of MDMA; Clark delivers keynote at Microdose's 3rd annual Wonderland Conference
- **2024** — Named an Elite Disruptor by PM360; Terran advances late-stage CNS assets and NM-101 neuroimaging software

## Achievements

- Named inventor on over 200 patent applications in neuropsychiatry
- Sole inventor on the world's first patented new forms of psilocybin and MDMA
- Built one of the largest psychedelic development programs in the industry
- Developed orally active versions of DMT and 5-MeO-DMT
- Licensed late-stage assets from Sanofi and Pierre Fabre
- Delivered NM-101, described as the world's first FDA-cleared software for neuromelanin MRI analysis
- Recognized as a PM360 Elite 2024 Disruptor

## Latest updates

- **2024-02** — Terran's most recent funding round; company continues advancing its CNS pipeline and drug design engine
- **2024-01** — Recognized as a PM360 Elite 2024 Disruptor for shaking up the neuropsychiatric therapeutics industry

## Links

- Website: https://terranbiosciences.com
- LinkedIn: http://www.linkedin.com/in/sam-clark-md-phd-133139199
- YouTube: https://www.youtube.com/watch?v=MtlWDwXnZ6k

---

Profile page: https://yespress.io/sam-clark
Published by YesPress — https://yespress.io
Last updated: 2026-07-01